Moderna (MRNA) to Release Quarterly Earnings on Friday

Key Points

• Moderna will report Q4 2025 results before the market opens on Friday, Feb. 13, 2026, with analysts projecting ($2.79) EPS and $611.14M in revenue; the earnings call is scheduled for 8:00 AM ET.
• In the prior quarter Moderna posted ($0.51) EPS—beating estimates—on $1.02B of revenue, though revenue was down 45.4% year‑over‑year, and analysts now expect roughly -$10 EPS for the current fiscal year and -$7 EPS for the next.
• Shares opened at $40.87 (down ~4.4%) with a market cap near $16B, while consensus analyst sentiment is a "Reduce" rating with an average price target of $28.77, and insiders have recently sold stock (director Noubar Afeyan sold 23,853 shares).

Moderna (NASDAQ:MRNA - Get Free Report) is projected to post its Q4 2025 results before the market opens on Friday, February 13th. Analysts expect Moderna to post earnings of ($2.79) per share and revenue of $611.14 million for the quarter. Individuals can find conference call details on the company's upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 13, 2026 at 8:00 AM ET.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($2.15) by $1.64. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $893.29 million. During the same period in the prior year, the firm posted $0.03 EPS. The business's revenue for the quarter was down 45.4% on a year-over-year basis. On average, analysts expect Moderna to post $-10 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Moderna Stock Down 4.4%

MRNA opened at $40.87 on Friday. Moderna has a 52-week low of $22.28 and a 52-week high of $55.20. The company has a 50 day moving average of $35.35 and a two-hundred day moving average of $29.54. The company has a market cap of $15.97 billion, a P/E ratio of -5.06 and a beta of 1.32.

Insider Activity at Moderna

In related news, Director Noubar Afeyan sold 23,853 shares of the firm's stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $29.48, for a total transaction of $703,186.44. Following the transaction, the director directly owned 3,924 shares in the company, valued at $115,679.52. This trade represents a 85.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 10.90% of the company's stock.

Institutional Investors Weigh In On Moderna

Institutional investors and hedge funds have recently bought and sold shares of the business. Invesco Ltd. grew its holdings in shares of Moderna by 15.7% during the third quarter. Invesco Ltd. now owns 8,216,163 shares of the company's stock valued at $212,223,000 after purchasing an additional 1,115,131 shares during the last quarter. Worldquant Millennium Advisors LLC bought a new position in Moderna during the 2nd quarter worth $23,192,000. Bank of America Corp DE increased its position in Moderna by 84.3% in the second quarter. Bank of America Corp DE now owns 1,779,309 shares of the company's stock worth $49,091,000 after buying an additional 813,974 shares during the period. Theleme Partners LLP lifted its stake in Moderna by 8.6% in the second quarter. Theleme Partners LLP now owns 7,868,810 shares of the company's stock valued at $217,100,000 after buying an additional 626,420 shares during the last quarter. Finally, Jump Financial LLC boosted its holdings in shares of Moderna by 1,920.3% during the third quarter. Jump Financial LLC now owns 498,460 shares of the company's stock valued at $12,875,000 after acquiring an additional 473,788 shares during the period. Institutional investors and hedge funds own 75.33% of the company's stock.

Analyst Ratings Changes

A number of research firms recently weighed in on MRNA. UBS Group lowered shares of Moderna from a "buy" rating to a "neutral" rating and lowered their price target for the company from $40.00 to $34.00 in a report on Tuesday, January 6th. Piper Sandler reissued an "overweight" rating on shares of Moderna in a research report on Monday, December 1st. Royal Bank Of Canada reaffirmed a "sector perform" rating on shares of Moderna in a research report on Monday, January 12th. BMO Capital Markets upgraded Moderna from a "market perform" rating to a "buy" rating in a research note on Monday, January 12th. Finally, Citigroup restated a "neutral" rating on shares of Moderna in a research note on Monday, January 19th. Two research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and five have given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Reduce" and an average price target of $28.77.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company's platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna's flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.